News

Perfect conclusion of the 12th Five-Year Plan major new drug creation project

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-06-01
  • Views:0

(Summary description)  The New Drug Special Programme is a science and technology programme that focuses on major strategic products and major industrialisation targets of the country, and carries out integrated and coordinated research within a set time frame. The implementation period is from 2008 to 2020, and is implemented in phases according to the focused development strategy of "paving, combing and highlighting" in the three five-year plans. The overall goal of the new drug program is to develop and technologically transform a number of drugs for 10 types of major diseases, including malignant tumours, to improve the national drug innovation system, to enhance independent innovation capabilities, to accelerate the development of the pharmaceutical industry, and to accelerate the transformation of China's pharmaceutical R&D from generic to innovative and the pharmaceutical industry from a large country to a strong one.

Perfect conclusion of the 12th Five-Year Plan major new drug creation project

(Summary description)  The New Drug Special Programme is a science and technology programme that focuses on major strategic products and major industrialisation targets of the country, and carries out integrated and coordinated research within a set time frame. The implementation period is from 2008 to 2020, and is implemented in phases according to the focused development strategy of "paving, combing and highlighting" in the three five-year plans. The overall goal of the new drug program is to develop and technologically transform a number of drugs for 10 types of major diseases, including malignant tumours, to improve the national drug innovation system, to enhance independent innovation capabilities, to accelerate the development of the pharmaceutical industry, and to accelerate the transformation of China's pharmaceutical R&D from generic to innovative and the pharmaceutical industry from a large country to a strong one.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-06-01
  • Views:0

 

  The New Drug Special Programme is a science and technology programme that focuses on major strategic products and major industrialisation targets of the country, and carries out integrated and coordinated research within a set time frame. The implementation period is from 2008 to 2020, and is implemented in phases according to the focused development strategy of "paving, combing and highlighting" in the three five-year plans. The overall goal of the new drug program is to develop and technologically transform a number of drugs for 10 types of major diseases, including malignant tumours, to improve the national drug innovation system, to enhance independent innovation capabilities, to accelerate the development of the pharmaceutical industry, and to accelerate the transformation of China's pharmaceutical R&D from generic to innovative and the pharmaceutical industry from a large country to a strong one.

   In 2012, with a tiny scale of 11 people, Shengshi Tai Ke independently undertook the national 12th Five-Year Plan major new drug creation project, so that our research and development of Class I innovative hypoglycemic drugs into the national support track. Through the joint efforts of all our colleagues, we were able to complete the task in excess of our mission and won the praise of the evaluation experts, and concluded the project perfectly. Two patents were granted, one clinical approval was granted and Yu Qiang, the founder and CEO of Centurion, was selected as the subject leader of the National Thousand Talents Program. The new hypoglycemic drug Shengliptin has entered the clinical stage with promising results and continues to receive support from the National 13th Five-Year Plan, led by Mr. Yu's partner, Mr. Ding Torping, Chairman of Shengshi Tai Ke.

Project (subject) task acceptance comments.

The project has exceeded the task target and developed a new dipeptidyl peptidase targeted hypoglycemic drug (Shengliptin phosphate) with independent intellectual property rights, which has obtained relevant clinical approvals and two patent authorisations. It is a new class I chemical drug with good innovation and independent intellectual property rights, and has obtained the relevant clinical approval. The project leader has been selected as one of the Thousand Talents Program, and the team building has been effective. The project has exceeded its target, obtained clinical approval for a new class I chemical drug and two patents, and is recommended to be accepted.

The

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.
2023-04-20

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO